Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 18;6(1):MMT14.
doi: 10.2217/mmt-2018-0008. eCollection 2019 Mar.

Application of CO2 laser evaporation in locally advanced melanoma

Otis M Vrielink  1   1 , Schelto Kruijff  1   1 , Barbara L van Leeuwen  1   1 , Jan Ln Roodenburg  2   2
Affiliations

Application of CO2 laser evaporation in locally advanced melanoma

Otis M Vrielink et al. Melanoma Manag. .

Abstract

Aim: This study aims to investigate the role of CO2 laser evaporation in the treatment of melanoma patients with satellite or in-transit metastases.

Materials & methods: Patients who underwent CO2 laser evaporation were retrospectively included between November 2002 and August 2018. The Sharplan 40C CO2 laser was used with a high pulse wave mode. Data concerning patient and tumor characteristics, CO2 laser evaporation and subsequent therapies were collected.

Results: A total of 26 patients were included. Median duration of local control was 5.5 months. The median number of lesions evaporated per treatment was three (1-16); patients received a median of three (1-19) treatments.

Conclusion: In a selected group of melanoma patients with satellite or in-transit metastases, CO2 laser evaporation should be considered as treatment for local control.

Keywords: CO2 laser; in-transit; melanoma; metastases; satellite.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Melanoma patient with in-transit metastases eligible for CO2 laser therapy.
<b>Figure 2.</b>
Figure 2.. Swimmers plot of the course of disease and treatment history of all individual patients with satellite or in-transit metastases.
<b>Figure 3.</b>
Figure 3.. Treatment flow-chart for patients with satellite or in-transit metastases.
CT: Computed tomography; FDG-PET: Fludeoxyglucose-positron emission tomography; HILP: Hyperthermic isolation limb perfusion; ILI: Isolated limb perfusion.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68(1):7–30. - PubMed
    1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001;19(16):3635–3648. - PubMed
    1. Read RL, Haydu L, Saw RP, et al. In-transit melanoma metastases: Incidence, prognosis, and the role of lymphadenectomy. Ann. Surg. Oncol. 2015;22(2):475–481. - PubMed
    1. Stucky CC, Gray RJ, Dueck AC, et al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am. J. Surg. 2010;200(6):770–774. discussion 774–775. - PubMed
    1. Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann. Surg. Oncol. 2005;12(8):587–596. - PubMed

LinkOut - more resources